EX-10.52
from 10-K
91 pages
[***] = Certain Portions of This Document, Marked With Asterisks, Have Been Redacted Because the Identified Portions Are (I) Not Material and (II) Treated as Private or Confidential by the Registrant Exclusive License and Collaboration Agreement by and Between Arrowhead Pharmaceuticals, Inc. and Novartis Pharma AG August 29, 2025 [***] = Certain Portions of This Document, Marked With Asterisks, Have Been Redacted Because the Identified Portions Are (I) Not Material and (II) Treated as Private or Confidential by the Registrant Exclusive License and Collaboration Agreement
12/34/56
EX-10.5
from 10-Q
1 page
R From the Desk Of: Patrick O’brien Chief Operating Officer and General Counsel May 9, 2025 Ken Myszkowski, CFO Arrowhead Pharmaceuticals, Inc. Regards, /S/ Patrick O’brien Patrick O’brien Accepted: /S/ Ken Myszkowski Ken Myszkowski 177 E. Colorado Blvd. Suite 700 Pasadena, Ca 91105 WWW.ARROWHEADPHARMA.com
12/34/56
EX-10.3
from 10-Q
106 pages
[***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Exclusive License and Collaboration Agreement by and Between Arrowhead Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. November 25, 2024
12/34/56
